Zepzelca (Lurbinectedin) Patent Expiration, LOE Window & CMS Spending
Zepzelca (Lurbinectedin) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2029-12-13, 0 AB generics, $19.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Jazz Pharmaceuticals |
| FDA Application & Pathway | N213702 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-12-13 |
| Last Listed Patent or Exclusivity Date | 2029-12-13 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $19.9M |
| 2024 Medicare Part D Spend | $2.6M |
| 2024 Medicaid Spend | $17.3M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.